Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interaction between smoking and <i>HLA-A*02:01</i> in multiple sclerosis progression.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study.

Annals of neurology·2026
Same author

Explainable AI for MRI Alzheimer's disease classification: A comparative analysis.

NeuroImage·2026
Same author

Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003-2022).

Neurology·2026
Same author

Comorbidities for Predicting Progression Independent of Relapse Activity in Multiple Sclerosis Treated With B-Cell Depletion.

European journal of neurology·2026
Same author

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.

Neurology and therapy·2026

Related Experiment Video

Updated: Jun 16, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.1K

Association between brain volume and disability over time in multiple sclerosis.

Thomas Moridi1,2, Leszek Stawiarz1, Kyla A McKay1

  • 1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Multiple Sclerosis Journal - Experimental, Translational and Clinical
|December 26, 2022
PubMed
Summary

Brain atrophy in multiple sclerosis (MS) is more strongly linked to disability in older adults. Grey matter volume loss, not just lesions, predicts long-term MS progression and cognitive decline.

Keywords:
brain atrophydisabilitymagnetic resonance imagingmultiple sclerosis

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.1K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

Related Experiment Videos

Last Updated: Jun 16, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.1K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.1K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

Area of Science:

  • Neuroimaging
  • Neurology
  • Clinical Research

Background:

  • Previous multiple sclerosis (MS) brain atrophy studies often used cross-sectional designs.
  • Limited clinical outcomes were assessed in prior MS brain atrophy research.

Purpose of the Study:

  • To determine which brain and lesion volume metrics best predict long-term disability in MS.
  • To investigate if MRI-clinical associations in MS change with patient age.

Main Methods:

  • Acquired MRI and clinical data from a Swedish MS cohort (n=989).
  • Utilized FreeSurfer and SPM for brain parenchymal, grey matter, white matter, and lesion volume analysis.
  • Employed mixed-effects and rolling regression models for statistical analysis.

Main Results:

  • MRI-clinical associations strengthened significantly after age 40-50.
  • Low baseline grey matter fractions predicted increased disability (EDSS, MSIS-29) and cognitive decline (SDMT).
  • Grey matter atrophy was a stronger long-term predictor than lesion volumes.

Conclusions:

  • The predictive power of MRI-clinical associations in MS increases with age.
  • Grey matter volume fractions are more robust predictors of long-term MS disability than lesion volumes.